Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling

Attribution of specific roles to the two ubiquitously expressed PI 3-kinase (PI3K) isoforms p110 alpha and p110 beta in biological functions they have been implicated, such as in insulin signalling, has been challenging. While p110 alpha has been demonstrated to be the principal isoform activated downstream of the insulin receptor, several studies have provided evidence for a role of p110 beta. Here we have used isoform-selective inhibitors to estimate the relative contribution of each of these isoforms in insulin signalling in adipocytes, which are a cell type with essential roles in regulation of metabolism at the systemic level. Consistent with previous genetic and pharmacological studies, we found that p110 alpha is the principal isoform activated downstream of the insulin receptor under physiological conditions. p110 alpha interaction with Ras enhanced the strength of p110 alpha activation by insulin. However, this interaction did not account for the selectivity for p110 alpha over p110 beta in insulin signalling. We also demonstrate that p110 alpha is the principal isoform activated downstream of the beta-adrenergic receptor (beta-AR), another important signalling pathway in metabolic regulation, through a mechanism involving activation of the cAMP effector molecule EPAC1. This study offers further insights in the role of PI3K isoforms in the regulation of energy metabolism with implications for the therapeutic application of selective inhibitors of these isoforms.

Automated summary

The study found that p110α plays a key role in the activation downstream of both the insulin receptor and the beta-adrenergic receptor, with its interaction with Ras enhancing its activation strength by insulin. This offers further insights into the role of PI3K isoforms in energy metabolism regulation and potential therapeutic applications.